Drug
XTR004
XTR004 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
2
50%
Ph phase_3
1
25%
Phase Distribution
1
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)
Trials by Status
completed250%
terminated125%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_3
Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)
NCT07439133
terminatedphase_2
Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis
NCT07187895
completedphase_2
Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD
NCT05885841
completedphase_1
A Study of XTR004 Radiotracer in Healthy Volunteers
NCT05195879
Clinical Trials (4)
Showing 4 of 4 trials
NCT07439133Phase 3
Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)
NCT07187895Phase 2
Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis
NCT05885841Phase 2
Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD
NCT05195879Phase 1
A Study of XTR004 Radiotracer in Healthy Volunteers
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4